ABSTRACT：The in situ generation of siRNAs in living cells can greatly enhance the specificity and efficiency of gene therapy. Inspired by the natural molecular machines that organize different compartments sequentially in a limited space to facilitate cellular process, this work constructs a DNA nanomachine (DNM) by alternately hybridizing two pairs of DNA/RNA hybrids to a DNA scaffold generated by rolling circle amplification for highly efficient in situ siRNA assembly in living cells. After target cell-specific delivery of DNM, intracellular specific microRNA can work as a trigger to operate the DNM by initiating DNA cascade displacement reaction between DNA/RNA hybrids along the scaffold for continuous generation of siRNAs. Using miR-21 as a model, efficient siRNAs generation are achieved via DNA templated cascade reaction, which demonstrated impressive suppressions to VEGF mRNA and protein expressions in cells and in vivo tumour growth, and indicated promising application of the designed strategy in gene therapy.
3
Synthetic small interfering RNAs (siRNAs), which can intracellularly silence disease-causing genes, have been used as a class of medicines to treat cancers and a wide range of diseases such as amyotrophic lateral sclerosis, Huntington's disease (HD), Alzheimer's disease (AD), and Parkinson's disease (PD). [1] [2] [3] [4] One of the biggest challenges in RNA interfering (RNAi) based therapeutics is delivering the synthetic siRNAs into cells due to their cell impermeability and susceptibility to degradations. [5] [6] [7] Although a variety of nanoparticles, polymers, and DNA structures have been used as carriers for siRNA delivery, [8] [9] [10] [11] [12] the unavoidable leakage of in vitro synthesized siRNA and uncontrollable degradation as well as "off-target" toxicity diminish gene therapy efficiency. 13, 14 Therefore, in situ generation of siRNA in target cells is an appropriate approach to enhance the specificity and efficiency of gene therapy, and several DNA/RNA hybridization/displacement reactions have been applied in living cells to in situ generate siRNA for gene therapies. 15, 16 However, the assembly efficiencies of current intracellular siRNA generation approaches through the spontaneous collisions of two DNA/RNA hybrids in molecularly crowded intracellular environment are limited due to the lacks of controllability and the low reaction rates. 15 Developing a controlled siRNA assembly system with high reaction efficiency in dynamically changing cytoplasm is of great significance to precise gene therapy. 17, 18 The naturally occurring intracellular synthesis is relied on natural molecular machines that can organize different compartments sequentially in a limited space to carry out machinery work in tandem with one another to facilitate reaction process. [19] [20] [21] A large number of natural intracellular molecular machines are composed of nucleic acid scaffolds such as transposons, spliceosomes, and ribosomes, which offer high reaction efficiency and specificity due to Watson-Crick base pairing. 22, 23 Inspired by the natural nucleic acid templated synthesis, programmable DNA nanostructures have been applied in vitro to assist cascade enzymatic reactions by substrate channeling 24, 25 and cofactor, 26 as well as to guide sequence-defined polymer and peptide synthesis. [27] [28] [29] [30] The nucleic acid templated small reaction area confines free diffusion of reactants and enhances their local concentrations, which can accelerate the reaction and greatly improve reaction efficiency. 31, 32 However, the application of DNA templated synthetic reactions has not been extended into living cells due to the involvement of exotic enzymes and catalyst.
Here we designed a strategy for in situ assembly of siRNA in living cells via microRNA (miRNA or miR) driving cascade reaction in a DNA nanomachine (DNM). The DNM was constructed by alternately hybridizing two pairs of DNA/RNA hybrids (DR and D'R') to a DNA scaffold. The proximity and precise arrangement of DR and D'R' along the scaffold guaranteed high reaction efficiency for intracellular siRNA generation. 33, 34 Using miR-21 as the specific model trigger to operate the DNA cascade strand displacement reaction in DNM, the continuous generation of siRNA was proceeded along the DNA scaffold, which was precisely controllable in time and space. The highly efficient gene silencing to suppress mRNA and protein expressions in cells and in vivo tumour growth demonstrated the practicability of this approach in gene therapy. Compared with the conventional gene interference technology, 35,36 the miR-21-triggered intracellular siRNA assembly with nucleic acids templated cascade reactions provides higher therapeutic specificity than that directly delivers siRNA into cells, and improves delivery stability by substituting the duplex siRNA with DNM. The high biocompatibility, impressive controllability and reaction efficiency of miR-21-triggered DNM could be further extended to in situ generation and biosensing of other nucleic acids and biomolecules.
RESULTS AND DISCUSSION
Principle of Intracellular SiRNA Assembly with MiRNA-Triggered DNM. As shown in Figure 1a , the DNA/RNA hybrids (DR and D'R') were alternatively arranged on a DNA scaffold, which was previously produced by rolling circle amplification (RCA), to form DNM. DR and D'R' 5 were synthesized by hybridizing ssDNA (D or D') with specific RNA (R or R') respectively, which formed two complementary bulge loop conformations. 37, 38 Here the 5' end of R is labelled with Cy3 (Cy3-R) for in situ monitoring the cellular process, and its 3' end has a toehold complementary to 5' end of specific miRNA. 39 The negatively charged DNM could form stable nanocomposite with cationic folic acid modified polyethylenimine (FPEI) to facilitate target cell-specific delivery and assist the endosomal escape of DNM into the cytoplasm. 40 Afterward, intracellular specific miRNA could recognize the toehold of R and hybridize with the first 22 nucleotides of R starting from the 3'-end to open the bulge loop of DR. The released bulge loop of D worked as an activated toehold to react with the bulge loop of D' subsequently, which triggered the strand displacement reaction between DR and D'R' to generate dsDNA (DD') on the DNA scaffold and release both the siRNA (RR') and the miRNA from the DNM. 16, 38 The released miRNA triggered the next strand displacement reaction between DR and D'R' for continuously generating siRNA in living cells ( Figure 1b ).
Characterization of DNM and DNM/FPEI. The synthesis of DNM was demonstrated by
polyacrylamide gel electrophoresis (PAGE) analysis (Figure 2a ). The RCA product showed a band with much lower mobility (lane 3) than DNA primer and DNA cycle (lanes 1 and 2), while the hybridization mixture showed only one band with much lower mobility (lane 6) than DR and D'R' (lanes 4 and 5), suggesting the formation of DNA scaffold and the successful synthesis of DNM.
Both the products of RCA and DNM barely moved in polyacrylamide gels due to their large molecular masses and sizes. 41, 42 Atomic force microscopic (AFM) image of DNM demonstrated monodispersed branch-like structure with an average length of 250 ± 100 nm ( Figure 2b ).
Considering the 48-base length of DNA cycle (16 nm) 43 for forming the repeated sequences to hybridize DR and D'R', the DNM contained 16 ± 6 pairs of DR/D'R'. To further confirm the number, aminomethylcoumarin (AMCA)-labelled DNA primer, Cy3-R and Cy5-labelled R' were used to 6 synthesize the tricolor DNM. From the fluorescence signals of AMCA, Cy3 and Cy5 in the DNM, the ratios of DNM : DR : D'R' were about 1 : 16.9 : 17.0 ( Figure S1 ), which was consistent with the AFM result.
To evaluate the performances and applications of DNM, self-quenched DR (SQ-DR) was prepared with Cy3-R and corresponding quencher BHQ2-labelled D to synthesize a self-quenched DNM (SQ-DNM). Upon addition of 10% fetal bovine serum, the fluorescence recovery of free SQ-DR was much greater than the SQ-DNM ( Figure S2a ), suggesting that DNM provided good protection of DR against nuclease degradation. The melting temperature (Tm) of 77.6 o C indicated good thermal stability of the DNM ( Figure S2b and S2c).
The synthetic FPEI was verified with its 1 HNMR spectrum and the UV-VIS and FTIR spectra of FPEI, PEI and FA ( Figure S3 ). Zeta potential analysis also confirmed the formation of DNM/FPEI ( Figure S4 ), and the FPEI wrapping effectively compressed the size of DNM to around 100 nm ( Figure 2c and 2d ), which is more appropriate for cellular internalization. 44, 45 To demonstrate the effect of interval distance between DR and D'R' in DNM on the efficiency of siRNA generation, a serial of DNMs with different base numbers between DR and D'R' were prepared. In the presence of 10 nM miR-21, the highest siRNA generation efficiency indicated by the fluorescence intensity was achieved at 8-bases distance ( Figure S6 ). Hence, the DNM with 8-bases distance between DR and D'R' was used for subsequent experiments.
The kinetics for siRNA assembly via miRNA-triggered cascade strand displacement reaction of DR and D'R' in DNM was much quicker than that via random strand displacement reaction of DR and D'R' in homogeneous solution in the presence of miRNA ( Figure S7 ). The former could reach the maximum generation in 16 min, while the latter reached an equilibrium at 80 min, demonstrating the substantial acceleration and highly efficient generation of siRNA.
To demonstrate the high efficiency of siRNA generation via miR-21-triggered DNM, the yield of siRNA from DNM was evaluated in vitro at different miR-21 concentrations by measuring Cy3 fluorescence recovery from SQ-DNM, which increased with the increasing miR-21 concentration The specific cell transfection of DNM/FPEI was achieved by folic acid (FA) receptor-mediated cell endocytosis, which was demonstrated by the much lower fluorescence recovery of Cy3 after the cells were incubated with SQ-DNM/PEI than that from SQ-DNM/FPEI transfected cells (DNM/PEI, DNM/FPEI, Figure S13 ). The internalization of SQ-DNM/FPEI could be highly suppressed for the cells previously treated with excessive FA (FA+DNM/FPEI, Figure S13 ), proving that FA played important roles in the targeted delivery of DNM/FPEI to HeLa cells. 48 The transfection specificity was further verified by the negligible Cy3 fluorescence from the FA receptor-negative human epidermal HaCat cells after treated with SQ-DNM/FPEI ( Figure S14 ).
To unequivocally evaluate the internalization pathway of the DNM/FPEI into the cells, a series of inhibitors including NaN3, wortmannin, genistein and sucrose were used to selectively block different cellular uptake processes ( Figure S15 ). An obvious decrease in cellular uptake was observed when the cells were incubated with NaN3, indicating the energy-dependent internalization of DNM/FPEI. 49 Figure S18a ), which was also verified by flow cytometric assay ( Figure S18b ). The VEGF mRNA and VEGF protein expressions in HepG2 cells treated with 100 nM DNM/FPEI were inhibited by about 46.0% and 49.7%, respectively ( Figure S19a and S19b), and the cell proliferation decreased to 57.0% along with the raised apoptosis rate of 56.5% compared with the untreated cells and the cells treated with NC-DNM/FPEI ( Figure S19c and S19d), indicating the potential therapeutic effect for various cancer types.
In Vivo Therapeutic Applicability. The antitumour efficacy of DNM via inhibition of VEGF expression from in vivo generated siRNA was investigated with mice bearing HeLa xenograft tumour. DNM/FPEI, NC-DNM/FPEI and NR-DNM/FPEI were intravenously injected into these mice every two days, respectively, and the inhibition efficacy towards tumour growth was monitored.
DNM/FPEI presented effective inhibition efficacy towards tumour growth, while no therapeutic effect was observed for NC-DNM/FPEI and NR-DNM/FPEI treated mice compared with the control mice group (PBS injected) ( Figure 6 ), indicating very high antitumour efficacy of DNM/FPEI.
During the experiment period of 14 days, these mice did not show obvious variation in their body weights ( Figure S19 ), indicating the satisfactory biocompatibility of DNM/FPEI. Thus in situ siRNA generation with DNM was a promising approach for highly efficient cancer therapy.
CONCLUSIONS
This work designs a miRNA triggered DNM to in situ assemble siRNA via cascade strand displacement reaction in cells. The highly efficient siRNA generation shows great suppression to miRNA-specific mRNA expression and protein synthesis in living cells. The DNM can be conveniently synthesized via alternately hybridizing two pairs of DNA/RNA hybrids to a DNA scaffold generated by rolling circle amplification, and shows satisfactory biocompatibility and good stability. Upon miRNA triggering, specific siRNA can be continuously assembled along the scaffold in a relatively short time due to the confined reaction area, which provides high reaction efficiency.
Using VEGF as a model target, the continuously assembled siRNA via nucleic acids template can efficiently inhibit the proliferation of HeLa cells and the growth of HeLa xenograft tumour, and show exciting antitumour efficacy. This strategy can be easily extended for in situ generation of other genes by changing the corresponding hybrid pairs, thus possesses promising application in biosensing and precise gene therapy. The mismatched bases were shown in underlined. All of the DNA were synthesized and purified by Sangon Biotech Co., Ltd (Shanghai, China). Their sequences were listed in Table S1 . AFM Imaging. 6 µL sample was deposited on freshly cleaved mica surface and incubated for 2 min. After the solvent water was absorbed with filter paper, 20 µL ultrapure water was twice added 16 to wash the mica. The mica was then dried with a nitrogen flow and scanned in tapping mode. In Vitro SiRNA Generation. To assess the in vitro generation of miR-21 controlled siRNA, 6 μL miR-21 with various concentrations were added in 54 μL of 100 nM SQ-DNM solution to incubate at 37 o C for 60 min, respectively. The resulting mixtures were immediately subjected to fluorescence measurements. Fluorescence spectra were recorded with excitation at 510 nm. The slit width was set as 5 nm for the excitation and 5 nm for the emission. The in vitro siRNA generation was also performed by mixing 54 μL of 100 nM SQ-DR and 100 nM D'R' with 6 μL miR-21 at various concentrations to incubate under the same condition for comparing the generation efficiency.
METHODS

Reagents
Serum Stability
For FRET measurements, tetramethylrhodamine (TAMRA)-labelled R and 5-carboxyfluorescein (FAM)-labelled R' were used as components to assemble bicolor DNM. The fluorescence spectra were recorded with excitation at 488 nm and the excitation and emission slit widths of 5 nm.
Preparation of Folic Acid Modified Polyethyleneimine (FPEI).
After EDC (10 mg) and NHS (20 mg) were mixed with 20 mL of saturated folic acid (0.0016 mg/mL) to react at room temperature for 40 min, polyethyleneimine (PEI) solution (5 mL, 1 mg/mL) was injected into the mixture to incubate at room temperature for 48 h with stirring. The reaction product was purified through dialysis with a membrane (MWCO: 7,000) for 6 days, and then freeze-dried under vacuum to obtain FPEI. For nuclear localization imaging, HeLa cells were incubated with 100 nM SQ-DNM/FPEI for 3 h followed by staining with 5 μg/mL DAPI for 10 min. DAPI was excited at 405 nm and the fluorescence signal was collected from 450 to 500 nm.
Assembly
Endocytosis Pathway of DNM/FPEI. The endocytosis pathway was examined as follows:
after HeLa cells were seeded in confocal dishes via 24-h incubation, 450 mM sucrose, 200 μg/mL genistein, 50 nM wortmannin and 10 mM NaN3 as uptake inhibitors were added into different cell-adhered dishes to inhibit clathrin, caveolae, macropinocytosis and energy dependent endocytosis, respectively. 48, 49 After incubation for 30 min at 37 o C, these cells were loaded with SQ-DNM/FPEI nanocomposite, during which the inhibitors were maintained, to perform the flow cytometric analysis for measuring the uptake amount of SQ-DNM/FPEI. injections were performed every other day for five times and meanwhile the tumour sizes were measured every 2 days by a digital caliper for 14 days. The tumour volumes were calculated as V = (L×W 2 )/2, where L and W are the length and width of the tumour, respectively.
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